On May 13th, 2011, CytRx Corporation (NASDAQ:CYTR) sold all pre-clinical & clinical data, intellectual-property rights and its other assets related to these compounds to Orphazyme ApS.CytRx Corporation (NASDAQ:CYTR) stock in last trading day opened at $5.46, traded the day range of $5.45 – $6.30, and closed at $5.79. The stock showed a positive performance of 10.08% in previous trading session.
Galena Biopharma Inc (NASDAQ:GALE) will probably get a lot of new attention over the next few days and smart traders know the more new people looking at a stock the better the odds of tradeable price swings. This is especially true for over the counter stocks where investor awareness campaigns are the primary market drive.In last trading activity, Galena Biopharma Inc(NASDAQ:GALE) traded 105.24 million shares and the average volume of the stock was recorded as 6.03millionshares. The 52 week range of the stock is $1.48 – $4.85. The stock was advanced 12.35% by closing at $4.82.
Idera Pharmaceuticals Inc (NASDAQ:IDRA) is a clinical-stage biotechnology company engaged now adays in the discovery and development of novel synthetic deoxyribonucleic acid DNA.Idera Pharmaceuticals Inc (NASDAQ:IDRA) stock on December 30, 2013, recorded a rise of 14.13% and was in a range of $3.60 – $4.33 before closing at $5. Company’s 52-week low price is $0.19 and 52 week high price is $4.33.
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) focuses on discovering, developing, and delivering medicines to patients for diseases with significant unmet need. Its lead product candidates include IPI-145 and IPI-443, inhibitors of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K); Retaspimycin HCl, a heat shock protein 90 inhibitor; and IPI-940, an inhibitor of fatty acid amide hydrolase.Infinity Pharmaceuticals Inc.(NASDAQ:INFI) shares rise 7.58% in last trading session an was closed at $13.48, while trading in range of $12.48 – $13.89 Its return on equity ratio is recorded as -51.70% and its return on assets is -47.00%.